Study Title
ALLELE: Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy
Protocol ID
ALLELE (ATA129-EBV-302)
Condition/s
EBV post transplant
Diagnosis Stage
Refractory
Location
NSW, VIC, WA
Sponsor
Pierre Fabre Medicament
Links
Trial Status
Open
Sites
Perth Children's Hospital
The Royal Children's Hospital
The Children's Hospital at Westmead
The Royal Children's Hospital
The Children's Hospital at Westmead
Study Type
Treatment
Phase
Phase 3
Age Eligibility
no limits
International registry ID's
NCT03394365
| Study Title | ALLELE: Multicenter Open Label Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy |
|---|---|
| Protocol ID | ALLELE (ATA129-EBV-302) |
| Disease (Sub Disease) | EBV post transplant |
| Diagnosis Stage | Refractory |
| Location | NSW / VIC / WA |
| Sponsor | Pierre Fabre Medicament |
| Links | https://clinicaltrials.gov/ct2/show/NCT03394365 |
| Trial Status | Open |
| Trial Open Date | 29/12/2017 |
| Sites | Perth Children's Hospital / The Royal Children's Hospital / The Children's Hospital at Westmead |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | no limits |
| International registry ID's | NCT03394365 |